标题
Metronomic chemotherapy in ovarian cancer
作者
关键词
-
出版物
CANCER LETTERS
Volume -, Issue -, Pages 216469
出版商
Elsevier BV
发表日期
2023-11-04
DOI
10.1016/j.canlet.2023.216469
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Assessment of Homologous Recombination Deficiency in Ovarian Cancer
- (2023) Vikas Garg et al. CLINICAL CANCER RESEARCH
- Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial
- (2023) Oliver Dorigo et al. CLINICAL CANCER RESEARCH
- Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
- (2023) Debra L. Richardson et al. JAMA Oncology
- Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
- (2023) Piotr J. Wysocki et al. Cancers
- Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
- (2023) Elena Muraro et al. Cancers
- Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors
- (2023) Fine Aliyuda et al. CURRENT CANCER DRUG TARGETS
- Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
- (2022) Yeh Chen Lee et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The Time Toxicity of Cancer Treatment
- (2022) Arjun Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Priorities for cancer research in low- and middle-income countries: a global perspective
- (2022) C. S. Pramesh et al. NATURE MEDICINE
- Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.
- (2022) Ana Veneziani et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
- (2022) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
- (2022) Sidrah Shah et al. International Journal of Environmental Research and Public Health
- Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
- (2022) Antonios Revythis et al. International Journal of Environmental Research and Public Health
- Drug Development in Low- and Middle-Income Countries: Opportunity or Exploitation?
- (2022) Rakesh Jalali et al. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
- (2022) Paul DiSilvestro et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
- (2022) Benoit You et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
- (2022) Deborah K. Armstrong et al. Journal of the National Comprehensive Cancer Network
- Participation of Lower and Upper Middle–Income Countries in Oncology Clinical Trials Led by High-Income Countries
- (2022) Fidel Rubagumya et al. JAMA Network Open
- Optimal biological dose: a systematic review in cancer phase I clinical trials
- (2021) J. Fraisse et al. BMC CANCER
- The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
- (2021) Whitney N. Goldsberry et al. GYNECOLOGIC ONCOLOGY
- Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
- (2021) Mohamed A Ghonim et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Treatment Bridging with a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma
- (2021) Tarek H. Mouhieddine et al. Clinical Lymphoma Myeloma & Leukemia
- Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial
- (2021) Aparna Sharma et al. GYNECOLOGIC ONCOLOGY
- Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
- (2021) Evangelia Ioannidou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies
- (2021) Anindita Chakrabarty et al. Frontiers in Oncology
- The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
- (2021) Nicholas Pavlidis et al. Cancer Epidemiology
- Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
- (2021) Jonathan S. Berek et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment
- (2021) Racheal Louise Johnson et al. Cancers
- Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
- (2020) Luana Schito et al. EMBO Molecular Medicine
- A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer
- (2020) M.R. Hall et al. GYNECOLOGIC ONCOLOGY
- Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients
- (2020) Margaret I. Liang et al. GYNECOLOGIC ONCOLOGY
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer
- (2020) Emese Zsiros et al. JAMA Oncology
- Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
- (2020) Michele Moschetta et al. Annals of Translational Medicine
- Oral metronomic cyclophosphamide in advanced ovarian cancer
- (2019) Michela Villa et al. ANTI-CANCER DRUGS
- DNA double-strand break repair-pathway choice in somatic mammalian cells
- (2019) Ralph Scully et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors
- (2018) Paola Orlandi et al. BIOCHEMICAL PHARMACOLOGY
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
- (2018) Junjie Wu et al. CANCER LETTERS
- Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
- (2018) Gianfranco Natale et al. CANCER LETTERS
- Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
- (2018) Chun-Yan Lan et al. LANCET ONCOLOGY
- Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Radoslav Chekerov et al. LANCET ONCOLOGY
- The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
- (2018) Galaxia Rodriguez et al. Cancers
- Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction
- (2018) Emanuele Bruni et al. Frontiers in Pharmacology
- Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial
- (2017) C. Dinkic et al. GYNECOLOGIC ONCOLOGY
- Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
- (2017) Nicoletta Colombo et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- The Dualistic Model of Ovarian Carcinogenesis
- (2016) Robert J. Kurman et al. AMERICAN JOURNAL OF PATHOLOGY
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
- (2016) Hui Zhang et al. CELL
- Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry
- (2016) C.S. Bhugwandass et al. Current Oncology
- Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
- (2016) Tze-Sian Chan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study
- (2015) James S. Ferriss et al. GYNECOLOGIC ONCOLOGY
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine
- (2015) Sébastien Benzekry et al. SEMINARS IN CANCER BIOLOGY
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
- (2015) Sabine Taschner-Mandl et al. Oncotarget
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
- (2015) Abhishek D. Garg et al. Frontiers in Immunology
- Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression
- (2015) Chong-Sheng Chen et al. NEOPLASIA
- Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
- (2014) Gabriella Ferrandina et al. BMC CANCER
- Adaptive designs for identifying optimal biological dose for molecularly targeted agents
- (2014) Yong Zang et al. Clinical Trials
- Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry
- (2014) Nicole P.M. Ezendam et al. GYNECOLOGIC ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch
- (2014) Prabhat Singh Malik et al. Frontiers in Oncology
- Update on randomized trials on recurrent disease
- (2013) A. Gonzalez-Martin ANNALS OF ONCOLOGY
- Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology
- (2013) Mehmet Kucukoner et al. Asian Pacific Journal of Cancer Prevention
- Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
- (2013) Marta Vives et al. INTERNATIONAL JOURNAL OF CANCER
- The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
- (2013) Emma L. Barber et al. Journal of Gynecologic Oncology
- Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
- (2012) B. Sitohy et al. CANCER RESEARCH
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?
- (2012) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy
- (2012) Mariana S. Nars et al. INTERNATIONAL JOURNAL OF CANCER
- Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor
- (2012) Sachiko Ezoe International Journal of Environmental Research and Public Health
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
- (2011) Shiyu Zhang et al. GYNECOLOGIC ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms
- (2011) Hong Yan et al. PLoS One
- Control Dominating Subclones for Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies
- (2011) Shengwen Calvin Li et al. STEM CELLS AND DEVELOPMENT
- Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
- (2010) G. Schiavoni et al. CANCER RESEARCH
- Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
- (2010) Jalid Sehouli et al. JOURNAL OF CLINICAL ONCOLOGY
- Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
- (2010) Chi-An Chen et al. MOLECULAR THERAPY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
- (2010) Alfonso Sánchez-Muñoz et al. ONCOLOGY
- Cellular senescence: Its role in tumor suppression and aging
- (2009) Naoko Ohtani et al. CANCER SCIENCE
- The Angiogenic Switch: Implications in the Regulation of Tumor Dormancy
- (2009) L. Moserle et al. CURRENT MOLECULAR MEDICINE
- The significance of Treg cells in defective tumor immunity
- (2008) Agata Kosmaczewska et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Biology of HIF-1α
- (2008) A Weidemann et al. CELL DEATH AND DIFFERENTIATION
- Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas
- (2008) R. S. Kerbel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More